Registered Email™ e-delivery proof
Amgen enhanced its electronic clinical research system with RMail secure electronic messaging.
Amgen, an American multinational biopharmaceutical company headquartered in California, integrated RMail so that certain physician packages could be transmitted via Registered Email™ services with encryption when needed; importantly returning proof of delivery of disclosures to reduce risk. With RMail’s easy-to-use, cost-effective and award winning Registered Email™ service, Amgen was able to transmit essential documentation with returned delivery evidence, thereby complying with requirements.
Sending application automatically converts outbound messages of a certain type to Registered Email™ messages, transmitting via SMTP re-routing to RMail global networks, and receiving the analysis and delivery forensics sealed to delivered content and timestamps; the Registered Receipt™ proof record.